Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Omigard: Development discontinued

March 16, 2009 7:00 AM UTC

Cadence discontinued development of Omigard after the gel missed the primary endpoint of reduction of LCSIs vs. povidone iodine in the Phase III CLIRS trial to prevent infection from IV catheters (6% ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article